[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrhythmia-atrial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrhythmia-atrial":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100539105",false,"NCT06299514","RAFT - Pace &Ablate","Resynchronization for Ambulatory Heart Failure Trial in Patients With Chronic Atrial Fibrillation - Pharmacological Rate Control vs. Pace and Ablate With Conduction System Pacing","RAFT-P&A RCT","Inclusion Criteria:\n\n1. Patients with permanent AF\u002Fpersistent AF (in AF)\n2. Patients with NYHA Class II -IVa HF symptoms\n3. Guideline driven medical therapy (GDMT) for HF for at least 3 months:\n\n   * for those \\\u003C 75 years of age with an NT-proBNP of ≥ 600 ng\u002FL\n   * for those ≥ 75 years of age with an NT-proBNP ≥ 900 ng\u002FL, or ≥ 600 ng\u002FL if the patient has had a HF hospitalization within 1 year\n\nExclusion Criteria:\n\n1. In hospital patients needing intensive care or intravenous inotropic agent in the last 4 days\n2. Patients with a life expectancy of ≤ 1 year from non-cardiac cause or anticipating a transplant within 1 year\n3. Acute coronary syndrome \\\u003C4 weeks or coronary revascularization \\\u003C3months\n4. Unable or unwilling to provide informed consent\n5. Uncorrected primary valvular disease or prosthetic tricuspid valve\n6. Restrictive, hypertrophic, or irreversible form of cardiomyopathy\n7. Severe pulmonary diseases requiring oxygenation\n8. Patients with a known history of WHO Class I pulmonary hypertension (PH) which includes PH associated with CVD, collagen vascular disease, congenital shunts, cirrhosis and portal hypertension, HIV, hemoglobinopathies, schistosomiasis or drug-associated PH as well as those with high suspicion of irreversible pulmonary hypertension\n9. Patients enrolled in competitive clinical trials that will affect the objectives of this study\n10. Existing CRT\u002FBiVP\n11. Patients who are pregnant\n12. Guideline indication for CRT\n13. More than 20% pacing with an existing pacemaker\n14. Severe mobility limitations (ex. wheelchair bound and severe neurological conditions that limit mobility)","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"NA","Atrial fibrillation (AF) is an irregular heartbeat that can cause symptoms of skipped beats, shortness of breath, stroke, or in some cases fluid in the lungs or legs. Treating AF is mostly to do with slowing the heart rate down so that the heart can get a chance to regain some energy. In some cases, slowing the heart rate is not easy to achieve as some patients find it difficult to tolerate medications and suffer side effects from these treatments. In these instances, there might be a possibility to permanently control the heart rate by implanting a pacemaker in the heart and intentionally damaging a regulatory region of the heart called the atrioventricular (AV) node. Damaging the AV node by a procedure called ablation results in the AF not being able to influence the bottom chambers (the ventricles) resulting in a slow rhythm. Therefore, if a pacemaker is implanted then the heart rate can be completely regulated by the pacemaker.\n\nA complex pacemaker that stimulates both the right and left ventricles simultaneously (BiVP) has been used for the last decade prior to AV node ablation. More recently, a technique has been designed to reduce the number of leads in the heart, reduce procedure time and have a similar effect on the heart called Conduction System Pacing (CSP). There is not enough existing evidence to show that a pace and ablate strategy is superior to optimal medical therapy. We intend to compare the efficacy of CSP with AV node ablation to optimal medical therapy for treating AF.",[26,27,28,29],"Atrial Fibrillation","Heart Failure","Pacemaker","Arrhythmia Atrial","RECRUITING","2026-06-29",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2024-04-25",{"date":38,"type":20},"2029-12-31",{"name":40,"class":41},"Habib Khan","OTHER",12,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100624296","NCT07407790","The Southern-Norway Post-Stroke Atrial Fibrillation Study","SNAPS","Inclusion Criteria:\n\n* Patients hospitalized with an ischemic stroke or transient ischemic attack (TIA), including amaurosis fugax, occurring within the last 2 weeks.\n* Initial evaluation of CT and\u002For CT angiography and\u002For MRI supports a diagnosis of TIA or ischemic stroke.\n* Available smartphone and access to the ECG247-app to be able to participate in the study.\n* Estimated life span of \\>6 month\n* Permanent address in Norway\n* Informed Consent, Capable of giving signed informed consent or consent through proxy as described in Appendix which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical Conditions\n\n* Known AF or atrial flutter prior to inclusion\n* Concomitant use of anticoagulation therapy or established contraindication to its use. To date this includes apixaban, rivaroxaban, edoxaban, dabigatran, warfarin and indirect thrombin inhibitors (except for short term thrombosis prevention).\n* Implanted pacemaker, ICD or loop-recorder\n* \\>70% stenosis of carotid artery on ipsilateral side to the stroke on CT angiography or ultrasound\n* Pregnancy",{"count":50,"type":20},450,[23],"This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.\n\nThe study will include approximately 450 adults who have had a stroke or a transient \"mini-stroke\" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:\n\n* Group 1 (Intervention): Participants wear the \"ECG247 Smart Heart Sensor.\" This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.\n* Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a \"Holter monitor\" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.\n\nThe main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.",[54,55,56,57,29],"Atrial Fibrillation (AF)","Atrial Fibrillation (Prevention of Stroke)","Ischemic Stroke","Secondary Prevention",[59,60,61],"stroke","atrial fibrillation","anticoagulation","2026-02-05",{"date":64,"type":34},"2026-02-12",{"date":66,"type":34},"2026-01-10",{"date":68,"type":20},"2029-12",{"name":70,"class":71},"Sorlandet Hospital HF","OTHER_GOV",1,""]